Introduction

Collaborations in renal cell carcinoma research
L. A. Wood, M.A.S. Jewett

Conference Summary

Summary of the first annual Genitourinary Medical Oncology Conference Renal Cell Carcinoma Forum
L.A. Wood, B. Escudier, N. Reaume

Reviews

Current understanding of the molecular mechanisms of kidney cancer: a primer for urologists
D.L. Lim, R. Ko, S.E. Pautler

Combining differential expression, chromosomal and pathway analyses for the molecular characterization of renal cell carcinoma
K.A. Furge, K. Dykema, D. Petillo, M. Westphal, Z. Zhang, E.J. Kort, B.T. Teh

Current status of cytokine therapy in management of patients with metastatic renal cell carcinoma
A.K. Kapoor, S.J. Hotte

Systemic therapy for patients with advanced, unresectable or metastatic renal cell carcinoma: moving to guidelines
S.J. Hotte, A.K. Kapoor

Sunitinib therapy for metastatic renal cell carcinoma: recommendations for management of side effects
C. Kollmannsberger, D. Soulieres, R. Wong, A. Scalera, R. Gaspo, G. Bjarnason

Locally advanced renal cell carcinoma
M. Al Otaibi, S. Tanguay

New surgical horizons: the role of cytoreductive nephrectomy for metastatic kidney cancer
R.A. Rendon

Debate

Sunitinib, sorafenib and other systemic noncytotoxic kidney cancer therapies can and should be administered by urologists
L. Klotz

A medical oncologist is the most qualified specialist to provide systemic therapy for patients with advanced renal cell carcinoma
P. Venner

Epilogue

Renal cell carcinoma: currently the most interesting genitourinary malignancy
L.A. Wood, M.A.S. Jewett

Back to top